Campbell & Co Investment Adviser’s Fulgent Genetics FLGT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,014	Closed	-$710K	–	1178
2025 Q4	$710K	Buy	27,014 +5,423	+25%	+$141K	0.03%	700
2025 Q3	$488K	Sell	21,591 -5,470	-20%	-$113K	0.04%	740
2025 Q2	$538K	Buy	27,061 +9,217	+52%	+$180K	0.03%	761
2025 Q1	$302K	Buy	17,844 +5,433	+44%	+$92.5K	0.02%	847
2024 Q4	$229K	Sell	12,411 -42,147	-77%	-$823K	0.02%	929
2024 Q3	$1.19M	Buy	+54,558	New	+$1.22M	0.09%	373
2024 Q1	–	Sell	-21,738	Closed	-$628K	–	1194
2023 Q4	$628K	Sell	21,738 -29,962	-58%	-$802K	0.06%	604
2023 Q3	$1.38M	Buy	51,700 +42,495	+462%	+$1.45M	0.17%	172
2023 Q2	$341K	Buy	+9,205	New	+$321K	0.06%	602
2022 Q4	–	Sell	-8,985	Closed	-$343K	–	843
2022 Q3	$343K	Buy	8,985 +2,098	+30%	+$105K	0.08%	435
2022 Q2	$376K	Sell	6,887 -2,869	-29%	-$158K	0.1%	374
2022 Q1	$609K	Buy	9,756 +4,356	+81%	+$287K	0.16%	200
2021 Q4	$543K	Buy	+5,400	New	+$475K	0.19%	173

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Campbell & Co Investment Adviser's FLGT Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 27,014 shares — an estimated $710K sold.

Campbell & Co Investment Adviser first reported a position in FLGT in Q4 2021 and held it in 13 quarters. The position peaked at $1.38M in Q3 2023. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 27,014 Fulgent Genetics shares in Q1 2026, an estimated $710K.
Campbell & Co Investment Adviser first reported a position in Fulgent Genetics in Q4 2021 and held it in 13 quarters.
Campbell & Co Investment Adviser's Fulgent Genetics position peaked at $1.38M in Q3 2023.
157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.